P/E của cổ phiếu PFE là bao nhiêu?

PFIZER INC (PFE) hiện giao dịch ở mức P/E 15.68 lần.

ROE của cổ phiếu PFE là bao nhiêu?

PFIZER INC có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 8.31%.

Tỷ suất cổ tức của PFE là bao nhiêu?

PFIZER INC có tỷ suất cổ tức 6.84%.

Điểm chất lượng (Quality Score) của PFE là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của PFE ở mức 77/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu PFE không?

Điểm AI Timing của PFE là 50/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu PFE thuộc ngành nào?

PFIZER INC được xếp vào ngành Healthcare >> Drug Manufacturers - General trên sàn NYSE

Cổ phiếu PFE (NYSE) | PFIZER INC – Phân tích Deepscope

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

PFE AI Analysis Summary

Our AI summary for PFE: PFIZER INC (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 15.68, ROE of 8.31%, a dividend yield of 6.84%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PFE

PFIZER INC

USD 25.01

0.10 (0.40%) Day Change

Watchlist Portfolio Compare Chart

15.68

P/E

0.71

D/E

8.3%

ROE

3.6%

ROA

6.84%

Div Yield

0.26

PEG

PFIZER INC
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 25.01 Price 0.10 (0.40%) Day Change	NEWS SCORE: 89

PFE Chất lượng tổng thể của cố phiếu Tốt ( Chất lượng = 77) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

77 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: Tỷ lệ ROE tương đối thấp
ROA quá thấp so với ROE
Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

54%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	1487
Magic Formula Rank by ROE	1487
Magic Formula Rank by ROIC	1821
Price	25.01
PBV / Sector	1.59 / 2.68 GOOD
Earning Per Share	1.31

PE / Sector	15.68 / 27.65
PEG or PE/Growth / Sector	0.26 / 0.28 GREAT
Average 1M Daily Value	842.80 M
Average 1W Daily Value	874.63 M

Yếu tố Kỹ thuật

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	11.83 / 17.30
NPM Average (%) / Sector	14.34 / 17.60 GOOD
NPM Change Average (%) / Sector	39.29 / 92.67 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	3.61 / 8.73
ROA Average (%) / Sector	5.59 / 8.56
ROA Change Average (%) / Sector	50.25 / 94.23 GREAT
ROE (%) / Sector	8.31 / 26.78
ROE Average (%) / Sector	12.30 / 13.05
ROE Change Average (%) / Sector	44.82 / 96.64 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

100%

Dividend (%) / Sector	6.84 / 2.40 GREAT
Dividend Average (%) / Sector	6.23 / 3.39 GREAT
Dividend Change Average (%) / Sector	19.60 / 4.92 GOOD

Chi tiết đăng ký

Analyze Date	2026-08-01 08:00:19
Symbol	PFE
Name	PFIZER INC
Sector	Healthcare >> Drug Manufacturers - General
Market	NYSE
Listed Shares	5,699.44 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	143,341.03 / 256,404.20

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 66 Hudson Boulevard East, New York, NY, United States, 10001-2192

Phone: 212 733 2323

Website: https://www.pfizer.com

Employees: 75,000

Sector: Healthcare >> Drug Manufacturers - General

Description: Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.